{"id":"aricept-donepezil-ir-10-mg","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"6-8","effect":"Muscle cramps"},{"rate":"5-10","effect":"Fatigue"},{"rate":"6-10","effect":"Insomnia"},{"rate":"2-3","effect":"Syncope"}]},"_chembl":{"chemblId":"CHEMBL502","moleculeType":"Small molecule","molecularWeight":"379.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Donepezil is a reversible inhibitor of the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. By inhibiting this enzyme, donepezil increases acetylcholine concentration in the central nervous system, enhancing cholinergic neurotransmission. This mechanism helps improve memory, attention, and cognitive function in patients with mild to moderate Alzheimer's disease.","oneSentence":"Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:15.417Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"},{"name":"Cognitive decline associated with Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT00566501","phase":"PHASE3","title":"Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-12-14","conditions":"Alzheimer's Disease","enrollment":915},{"nctId":"NCT02079246","phase":"PHASE3","title":"Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-04-07","conditions":"Alzheimer's Disease","enrollment":1463},{"nctId":"NCT01276353","phase":"PHASE2","title":"A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-01","conditions":"Alzheimer's Type Dementia","enrollment":45},{"nctId":"NCT00478205","phase":"PHASE3","title":"Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-06","conditions":"Alzheimer's Disease","enrollment":1467}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Donepezil hydrochloride"],"phase":"phase_3","status":"active","brandName":"Aricept (donepezil IR 10 mg)","genericName":"Aricept (donepezil IR 10 mg)","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease. Used for Mild to moderate Alzheimer's disease, Cognitive decline associated with Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}